
  
    
      
        
        Today_NN the_DT possibilities_NNS for_IN a_DT medical_JJ journal_NN are_VBP almost_RB limitless_JJ ._. The_DT first_JJ medical_JJ
        journals_NNS reflected_VBD the_DT needs_NNS of_IN a_DT closed_VBN group_NN of_IN doctors_NNS ._. But_CC medicine_NN ,_, its_PRP$ place_NN in_IN the_DT
        world_NN ,_, and_CC the_DT dissemination_NN of_IN information_NN have_VBP changed_VBN utterly_RB ._. So_RB in_IN starting_VBG afresh_NN ,_,
        what_WP should_MD a_DT new_JJ medical_JJ journal_NN retain_VB ,_, and_CC what_WP should_MD it_PRP ditch_NN ?_.
        Most_JJS obviously_RB ,_, we_PRP should_MD throw_VB out_RP the_DT old_JJ way_NN of_IN disseminating_VBG information_NN ._. In_IN today_NN 's_POS
        electronic_JJ age_NN ,_, it_PRP is_VBZ no_DT more_RBR difficult_JJ ,_, and_CC it_PRP is_VBZ only_RB minimally_RB more_RBR costly_JJ ,_, to_TO provide_VB
        access_NN to_TO one_CD million_CD people_NNS than_IN it_PRP is_VBZ to_TO one_CD person_NN ._. So_IN the_DT revolutionary_JJ idea_NN of_IN anyone_NN
        being_VBG able_JJ to_TO read_VB any_DT article_NN is_VBZ possible_JJ ._. This_DT idea—open_NN access—which_NN completely_RB
        challenges_VBZ the_DT old_JJ subscription-based_JJ publishing_NN model_NN ,_, is_VBZ the_DT driving_VBG force_NN behind_IN the_DT
        launch_NN of_IN 
        PLoS_NNP Medicine_NNP ._. You_PRP can_MD download_NN and_CC distribute_VB articles_NNS without_IN
        restrictions_NNS (_( feel_VBP free_JJ to_TO make_VB a_DT thousand_CD copies_NNS ,_, translate_VB articles_NNS into_IN other_JJ languages_NNS ,_,
        put_VB articles_NNS into_IN books—just_NN give_VBP the_DT author_NN proper_JJ credit_NN )_) ._.
        We_PRP have_VBP also_RB changed_VBN the_DT way_NN we_PRP involve_VBP the_DT academic_JJ community_NN in_IN our_PRP$ journal_NN ._. Our_PRP$ large_JJ
        global_JJ editorial_NN board_NN reflects_VBZ the_DT diversity_NN of_IN medicine_NN today_NN and_CC is_VBZ intimately_RB involved_VBN
        in_IN what_WP we_PRP do_VBP ._. In_IN particular_JJ ,_, members_NNS of_IN the_DT editorial_NN board_NN are_VBP a_DT crucial_JJ part_NN of_IN our_PRP$ peer_VBP
        review_NN process_NN ._. As_IN academic_JJ editors_NNS they_PRP ,_, along_IN with_IN a_DT senior_JJ editor_NN at_IN the_DT journal_NN ,_, take_VB
        research_NN papers_NNS through_IN the_DT peer_NN review_NN process_NN in_IN a_DT way_NN that_IN we_PRP believe_VBP provides_VBZ the_DT most_RBS
        constructive_JJ and_CC fair_JJ review_NN ._. We_PRP are_VBP delighted_JJ that_IN members_NNS of_IN our_PRP$ editorial_NN board_NN have_VBP
        also_RB shown_VBN their_PRP$ support_NN for_IN our_PRP$ journal_NN by_IN submitting_VBG papers_NNS to_TO us_PRP ,_, even_RB before_IN we_PRP
        launched_VBD ._.
        What_WP will_MD we_PRP publish_VB ?_. The_DT research_NN article_NN on_IN malaria_NN in_IN this_DT issue_NN reflects_VBZ our_PRP$
        priority_NN of_IN publishing_NN papers_NNS on_IN diseases_NNS that_WDT take_VBP the_DT greatest_JJS toll_NN on_IN health_NN globally_RB ._.
        But_CC we_PRP will_MD also_RB publish_VB papers_NNS reporting_VBG a_DT substantial_JJ advance_NN in_IN any_DT specialty_NN ,_, whether_IN
        that_DT advance_NN is_VBZ in_IN public_JJ health_NN ,_, such_JJ as_IN the_DT paper_NN on_IN the_DT global_JJ burden_NN of_IN disease_NN ;_: drug_NN
        effects_NNS ,_, such_JJ as_IN the_DT paper_NN on_IN the_DT effect_NN of_IN HIV_NNP drugs_NNS on_IN lipids_NNS ;_: or_CC the_DT molecular_JJ
        understanding_NN of_IN disease_NN ,_, such_JJ as_IN the_DT paper_NN dissecting_VBG out_RP the_DT immune_JJ responses_NNS in_IN lung_NN
        disease_NN caused_VBN by_IN smoking_VBG ._.
        A_DT good_JJ general_JJ medical_JJ journal_NN should_MD also_RB be_VB a_DT place_NN where_WRB the_DT global_JJ medical_JJ community_NN
        can_MD discuss_VB together_RB what_WP matters_NNS to_TO them_PRP ._. The_DT magazine_NN section_NN of_IN 
        PLoS_NNP Medicine_NNP will_MD be_VB devoted_VBN to_TO comment_VB ,_, lively_JJ debate_NN ,_, and_CC diverse_JJ
        opinions_NNS ,_, in_IN particular_JJ giving_NN neglected_VBN voices_NNS and_CC diseases_NNS a_DT place_NN in_IN the_DT limelight_NN ._. In_IN
        this_DT issue_NN 's_POS magazine_NN section_NN you_PRP will_MD see_VB articles_NNS from_IN five_CD continents_NNS that_WDT cover_VBP a_DT huge_JJ
        range_NN of_IN topics_NNS ,_, from_IN basic_JJ sciences_NNS (_( such_JJ as_IN the_DT pathology_NN of_IN emphysema_NN )_) to_TO global_JJ public_JJ
        health_NN (_( such_JJ as_IN palliative_JJ care_NN in_IN developing_VBG countries_NNS )_) ._. You_PRP will_MD find_VB diverse_JJ
        opinions—for_NN example_NN ,_, on_IN whether_IN President_NNP Bush_NNP is_VBZ helping_VBG or_CC hindering_VBG Africa_NNP 's_POS progress_NN
        towards_IN tackling_VBG HIV_NNP ,_, and_CC on_IN whether_IN health_NN professionals_NNS should_MD routinely_RB screen_VB women_NNS for_IN
        domestic_JJ violence_NN (_( tell_VB us_PRP what_WP you_PRP think_VBP by_IN taking_VBG our_PRP$ poll_NN at_IN www_NN ._. plosmedicine_NN ._. org_NN )_) ._. And_CC
        you_PRP 'll_MD find_VB case-based_JJ learning_NN materials_NNS on_IN meningitis_NNS linked_VBN to_TO an_DT online_NN video_NN and_CC an_DT
        online_NN quiz_NN ._.
        
          
            The_DT revolutionary_JJ idea_NN of_IN anyone_NN being_VBG able_JJ to_TO read_VB any_DT article_NN is_VBZ possible_JJ ._.
          
        
        Interpretation_NNP of_IN results_NNS is_VBZ an_DT essential_JJ part_NN of_IN a_DT medical_JJ journal_NN 's_POS job_NN ._. Although_IN we_PRP
        expect_VBP that_IN many_JJ of_IN our_PRP$ readers_NNS will_MD be_VB doctors_NNS ,_, we_PRP hope_VBP readers_NNS will_MD range_VB from_IN patients_NNS
        wanting_VBG to_TO learn_VB about_IN the_DT latest_JJS research_NN on_IN their_PRP$ illness_NN ,_, to_TO teachers_NNS wanting_VBG to_TO use_VB an_DT
        article_NN in_IN the_DT classroom_NN ,_, to_TO policymakers_NNS ._. Hence_RB ,_, we_PRP have_VBP several_JJ levels_NNS of_IN comment_NN on_IN
        original_JJ research_NN ._. Perspectives_NNP ,_, written_VBN by_IN an_DT expert_NN ,_, are_VBP aimed_VBN at_IN readers_NNS who_WP are_VBP already_RB
        familiar_JJ with_IN the_DT topic_NN ._. Synopses_NNP ,_, written_VBN by_IN 
        PLoS_NNP Medicine_NNP 's_POS professional_JJ editors_NNS ,_, should_MD provide_VB any_DT health_NN
        professional_JJ with_IN a_DT quick_JJ introduction_NN to_TO an_DT article_NN ._. Patient_NNP summaries_NNS provide_VBP a_DT starting_NN
        point_NN for_IN patients_NNS to_TO assess_VB the_DT relevance_NN to_TO them_PRP of_IN a_DT research_NN paper_NN ._.
        We_PRP have_VBP decided_VBN not_RB to_TO be_VB part_NN of_IN the_DT cycle_NN of_IN dependency_NN that_WDT has_VBZ formed_VBN between_IN
        journals_NNS and_CC the_DT pharmaceutical_JJ industry_NN ,_, an_DT industry_NN that_WDT focuses_VBZ overwhelmingly_RB on_IN the_DT
        most_RBS profitable_JJ drugs_NNS ,_, thus_RB sidelining_VBG many_JJ of_IN the_DT world_NN 's_POS health_NN problems_NNS ._. Medical_JJ
        journals_NNS have_VBP allowed_VBN their_PRP$ interests_NNS to_TO become_VB aligned_VBN with_IN those_DT of_IN the_DT pharmaceutical_JJ
        industry_NN by_IN printing_VBG advertisements_NNS for_IN drugs_NNS ,_, publishing_NN trials_NNS designed_VBN by_IN drug_NN
        companies_NNS '_POS marketing_NN departments_NNS ,_, and_CC making_VBG profits_NNS on_IN reprints_VBZ used_VBN as_IN marketing_NN tools_NNS ._. 
        PLoS_NNP Medicine_NNP will_MD not_RB accept_VB advertisements_NNS for_IN pharmaceutical_JJ products_NNS
        or_CC medical_JJ devices_NNS ._. Our_PRP$ open-access_JJ license_NN allows_VBZ free_JJ distribution_NN of_IN articles_NNS ,_, so_RB PLoS_NNP
        cannot_NN benefit_NN from_IN exclusive_JJ reprint_VB sales_NNS ._. And_CC we_PRP consider_VBP as_IN the_DT lowest_JJS priority_NN for_IN
        publication_NN papers_NNS that_WDT are_VBP simply_RB aimed_VBN at_IN increasing_VBG a_DT drug_NN 's_POS market_NN share_NN without_IN
        obvious_JJ benefit_NN to_TO patients_NNS ._.
        We_PRP will_MD aim_VB to_TO have_VB the_DT highest_JJS levels_NNS of_IN transparency_NN in_IN our_PRP$ published_VBN papers_NNS ._. We_PRP
        require_VBP authors_NNS to_TO tell_VB us_PRP of_IN any_DT possible_JJ competing_VBG interests_NNS ;_: we_PRP in_IN turn_NN will_MD tell_VB
        readers_NNS about_IN them_PRP ._.
        But_CC ,_, information_NN flow_NN should_MD not_RB be_VB just_RB one-way_JJ ._. Our_PRP$ editorial_NN doors_NNS (_( or_CC at_IN least_JJS our_PRP$
        E-_NNP mail_NN boxes_NNS )_) are_VBP always_RB open_JJ ._. We_PRP want_VBP your_PRP$ feedback_NN on_IN the_DT journal_NN :_: send_VB us_PRP an_DT E-_NNP mail_NN or_CC
        submit_VB an_DT eLetter_NN about_IN any_DT article_NN in_IN the_DT journal_NN ,_, take_VB part_NN in_IN our_PRP$ polls_NNS ,_, contribute_VB
        ideas_NNS for_IN the_DT magazine_NN section_NN and_CC submit_VB original_JJ research_NN ._. 
        PLoS_NNP Medicine_NNP is_VBZ a_DT journal_NN for_IN the_DT global_JJ medical_JJ community_NN ;_: we_PRP invite_VB
        you_PRP to_TO join_VB in_IN ._.
      
    
  
